ConductScience.org, home

Paper36964001

Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.

Tamandjou C and 4 others. Vaccine, 2023. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Papers, record 36964001. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36964001

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
PubMed
Journal
Vaccine
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.81
iCite
Revised in PubMed
2024-09-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tamandjou CCynthia
2Auvigne VVincent
3Schaeffer JJustine
4Vaux SSophie
5Parent du Châtelet IIsabelle

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
Humans
Middle Aged
SARS-CoV-2
France
Antigenic Variation
Vaccination

Source PubMed

Download CSV of topics

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136402756Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections.Nat Commun2022https://conductscience.org/library/papers/36402756PubMed
233277323Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM.Sci Adv2021https://conductscience.org/library/papers/33277323PubMed
335172051Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.N Engl J Med2022https://conductscience.org/library/papers/35172051PubMed
436223534Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.N Engl J Med2022https://conductscience.org/library/papers/36223534PubMed
535862287
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep2022https://conductscience.org/library/papers/35862287PubMed
635662871Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021.Glob Epidemiol2022https://conductscience.org/library/papers/35662871PubMed
734001753Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.Epidemiology2021https://conductscience.org/library/papers/34001753PubMed
835793826Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.BMJ2022https://conductscience.org/library/papers/35793826PubMed
935417631Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.N Engl J Med2022https://conductscience.org/library/papers/35417631PubMed
1035699621Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.Science2022https://conductscience.org/library/papers/35699621PubMed
1136239934Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.JAMA Netw Open2022https://conductscience.org/library/papers/36239934PubMed
1234619098Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.Lancet2021https://conductscience.org/library/papers/34619098PubMed
1336338436Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.iScience2022https://conductscience.org/library/papers/36338436PubMed
145160433Attributable risk percent in case-control studies.Br J Prev Soc Med1971https://conductscience.org/library/papers/5160433PubMed
1635609888Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.BMJ2022https://conductscience.org/library/papers/35609888PubMed
1735249272Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.N Engl J Med2022https://conductscience.org/library/papers/35249272PubMed
1836379401Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic individuals in the omicron period: a cross-sectional study.Clin Microbiol Infect2023https://conductscience.org/library/papers/36379401PubMed
1935297591Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.N Engl J Med2022https://conductscience.org/library/papers/35297591PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
40028449All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data.F1000Res2024https://conductscience.org/library/papers/40028449PubMed
38966308Protection of Omicron Sub-Lineage Infection Against Reinfection with Another Omicron Sub-Lineage: Systematic Review, Meta-Analysis, and Meta-Regression - Worldwide, 2022-2023.China CDC Wkly2024https://conductscience.org/library/papers/38966308PubMed
38280109mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.Clin Exp Med2024https://conductscience.org/library/papers/38280109PubMed
38274635COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus2024https://conductscience.org/library/papers/38274635PubMed
37808897Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case-Control Study Based on the French National Health Data System.Open Forum Infect Dis2023https://conductscience.org/library/papers/37808897PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36964001

GET https://conductscience.org/api/papers/v1/36964001/authors